SRR10900596
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- ALLOGRAFT_REJECTION+0.400
- MYC_TARGETS_V2+0.400
- INTERFERON_GAMMA_RESPONSE+0.300
- INTERFERON_ALPHA_RESPONSE+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- DNA_REPAIR+0.100
- IL6_JAK_STAT3_SIGNALING+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- COAGULATION-0.400
- MYOGENESIS-0.400
- HEDGEHOG_SIGNALING-0.300
- HYPOXIA-0.300
- ADIPOGENESIS-0.200
- APICAL_JUNCTION-0.200
- APICAL_SURFACE-0.200
- BILE_ACID_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B9-01A-11R-A056-07 | — | E | 0.855 |
| 2 | d708a0d7-edda-46a8-b717-1b48c073c828 | — | — | 0.853 |
| 3 | MBCProject_1819_T1_RNA | — | C | 0.853 |
| 4 | MBCProject_0454_T1_RNA | — | B | 0.852 |
| 5 | 83a1d91a-3e74-4106-96d1-eec558404c29 | — | — | 0.829 |
| 6 | KG1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.823 |
| 7 | SRR975568 | — | — | 0.822 |
| 8 | MBCProject_1542_T2_RNA | — | D | 0.822 |
| 9 | SRR11296816 | — | — | 0.820 |
| 10 | BS_K17VQECG | high-grade glioma | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |